Selective serotonin reuptake inhibitors for migraine prophylaxis

Stephen Landy, Judy McGinnis, Dana Curlin, Steven Laizure

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The objective of this study was to assess the efficacy of sertraline in migraine prophylaxis. Other selective serotonin reuptake inhibitors have been studied for migraine prophylaxis, but this is the first report with sertraline. Twenty-seven subjects were enrolled and baseline assessment of migraine frequency and severity were measured over a 4-week period. Subjects were then randomized to receive placebo or sertraline in a double-blind fashion with headache frequency and severity measured over an 8-week period. Subjects completed a daily diary reporting the occurrence, severity, and degree of impairment associated with migraine. The headache index, a composite measure of migraine frequency and severity, scores did not significantly improve between assessments at baseline (20.8 ± 14.88), 8 weeks (17.6 ± 12.27), and 12 weeks (16.7 ± 6.38) in the treatment group (n=6) (P=0.956). This finding is compared to other studies with the serotonin selective reuptake inhibitors, fluoxetine, fluvoxamine, and paroxetine. The authors believe that the selective serotonin reuptake inhibitors are not as effective as conventional migraine prophylaxis medications such as β- blockers, tricyclic antidepressants, or divalproex sodium, but that in patients with comorbid depression who have failed conventional therapy selective serotonin reuptake inhibitors may he effective.

Original languageEnglish (US)
Pages (from-to)28-32
Number of pages5
JournalHeadache
Volume39
Issue number1
DOIs
StatePublished - Jan 1 1999

Fingerprint

Serotonin Uptake Inhibitors
Migraine Disorders
Sertraline
Headache
Fluvoxamine
Paroxetine
Tricyclic Antidepressive Agents
Fluoxetine
Valproic Acid
Placebos
Therapeutics

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Selective serotonin reuptake inhibitors for migraine prophylaxis. / Landy, Stephen; McGinnis, Judy; Curlin, Dana; Laizure, Steven.

In: Headache, Vol. 39, No. 1, 01.01.1999, p. 28-32.

Research output: Contribution to journalArticle

Landy, Stephen ; McGinnis, Judy ; Curlin, Dana ; Laizure, Steven. / Selective serotonin reuptake inhibitors for migraine prophylaxis. In: Headache. 1999 ; Vol. 39, No. 1. pp. 28-32.
@article{076f1383b5254727addca13a3bb040a9,
title = "Selective serotonin reuptake inhibitors for migraine prophylaxis",
abstract = "The objective of this study was to assess the efficacy of sertraline in migraine prophylaxis. Other selective serotonin reuptake inhibitors have been studied for migraine prophylaxis, but this is the first report with sertraline. Twenty-seven subjects were enrolled and baseline assessment of migraine frequency and severity were measured over a 4-week period. Subjects were then randomized to receive placebo or sertraline in a double-blind fashion with headache frequency and severity measured over an 8-week period. Subjects completed a daily diary reporting the occurrence, severity, and degree of impairment associated with migraine. The headache index, a composite measure of migraine frequency and severity, scores did not significantly improve between assessments at baseline (20.8 ± 14.88), 8 weeks (17.6 ± 12.27), and 12 weeks (16.7 ± 6.38) in the treatment group (n=6) (P=0.956). This finding is compared to other studies with the serotonin selective reuptake inhibitors, fluoxetine, fluvoxamine, and paroxetine. The authors believe that the selective serotonin reuptake inhibitors are not as effective as conventional migraine prophylaxis medications such as β- blockers, tricyclic antidepressants, or divalproex sodium, but that in patients with comorbid depression who have failed conventional therapy selective serotonin reuptake inhibitors may he effective.",
author = "Stephen Landy and Judy McGinnis and Dana Curlin and Steven Laizure",
year = "1999",
month = "1",
day = "1",
doi = "10.1046/j.1526-4610.1999.3901028.x",
language = "English (US)",
volume = "39",
pages = "28--32",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Selective serotonin reuptake inhibitors for migraine prophylaxis

AU - Landy, Stephen

AU - McGinnis, Judy

AU - Curlin, Dana

AU - Laizure, Steven

PY - 1999/1/1

Y1 - 1999/1/1

N2 - The objective of this study was to assess the efficacy of sertraline in migraine prophylaxis. Other selective serotonin reuptake inhibitors have been studied for migraine prophylaxis, but this is the first report with sertraline. Twenty-seven subjects were enrolled and baseline assessment of migraine frequency and severity were measured over a 4-week period. Subjects were then randomized to receive placebo or sertraline in a double-blind fashion with headache frequency and severity measured over an 8-week period. Subjects completed a daily diary reporting the occurrence, severity, and degree of impairment associated with migraine. The headache index, a composite measure of migraine frequency and severity, scores did not significantly improve between assessments at baseline (20.8 ± 14.88), 8 weeks (17.6 ± 12.27), and 12 weeks (16.7 ± 6.38) in the treatment group (n=6) (P=0.956). This finding is compared to other studies with the serotonin selective reuptake inhibitors, fluoxetine, fluvoxamine, and paroxetine. The authors believe that the selective serotonin reuptake inhibitors are not as effective as conventional migraine prophylaxis medications such as β- blockers, tricyclic antidepressants, or divalproex sodium, but that in patients with comorbid depression who have failed conventional therapy selective serotonin reuptake inhibitors may he effective.

AB - The objective of this study was to assess the efficacy of sertraline in migraine prophylaxis. Other selective serotonin reuptake inhibitors have been studied for migraine prophylaxis, but this is the first report with sertraline. Twenty-seven subjects were enrolled and baseline assessment of migraine frequency and severity were measured over a 4-week period. Subjects were then randomized to receive placebo or sertraline in a double-blind fashion with headache frequency and severity measured over an 8-week period. Subjects completed a daily diary reporting the occurrence, severity, and degree of impairment associated with migraine. The headache index, a composite measure of migraine frequency and severity, scores did not significantly improve between assessments at baseline (20.8 ± 14.88), 8 weeks (17.6 ± 12.27), and 12 weeks (16.7 ± 6.38) in the treatment group (n=6) (P=0.956). This finding is compared to other studies with the serotonin selective reuptake inhibitors, fluoxetine, fluvoxamine, and paroxetine. The authors believe that the selective serotonin reuptake inhibitors are not as effective as conventional migraine prophylaxis medications such as β- blockers, tricyclic antidepressants, or divalproex sodium, but that in patients with comorbid depression who have failed conventional therapy selective serotonin reuptake inhibitors may he effective.

UR - http://www.scopus.com/inward/record.url?scp=0032906373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032906373&partnerID=8YFLogxK

U2 - 10.1046/j.1526-4610.1999.3901028.x

DO - 10.1046/j.1526-4610.1999.3901028.x

M3 - Article

VL - 39

SP - 28

EP - 32

JO - Headache

JF - Headache

SN - 0017-8748

IS - 1

ER -